Concepts (171)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Failure, Acute | 8 | 2021 | 49 | 1.910 |
Why?
|
| Hepatopulmonary Syndrome | 4 | 2019 | 10 | 1.230 |
Why?
|
| Liver Cirrhosis | 8 | 2023 | 301 | 1.170 |
Why?
|
| Liver Transplantation | 9 | 2021 | 400 | 0.960 |
Why?
|
| Chemical and Drug Induced Liver Injury | 4 | 2021 | 131 | 0.960 |
Why?
|
| Liver Neoplasms | 3 | 2022 | 334 | 0.610 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2017 | 41 | 0.580 |
Why?
|
| Esophageal and Gastric Varices | 1 | 2016 | 47 | 0.520 |
Why?
|
| Registries | 3 | 2019 | 730 | 0.520 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2017 | 163 | 0.510 |
Why?
|
| Takotsubo Cardiomyopathy | 1 | 2014 | 14 | 0.490 |
Why?
|
| Decision Support Techniques | 1 | 2016 | 191 | 0.480 |
Why?
|
| Models, Theoretical | 1 | 2016 | 384 | 0.440 |
Why?
|
| Prognosis | 7 | 2021 | 2093 | 0.420 |
Why?
|
| Hepatic Veins | 1 | 2011 | 13 | 0.400 |
Why?
|
| Pulmonary Veins | 1 | 2011 | 56 | 0.390 |
Why?
|
| Endothelin-1 | 1 | 2011 | 122 | 0.360 |
Why?
|
| Severity of Illness Index | 10 | 2023 | 1851 | 0.350 |
Why?
|
| Cholangitis, Sclerosing | 1 | 2009 | 9 | 0.340 |
Why?
|
| Middle Aged | 21 | 2021 | 21119 | 0.320 |
Why?
|
| Herpesvirus 4, Human | 1 | 2007 | 30 | 0.300 |
Why?
|
| Humans | 29 | 2023 | 68549 | 0.290 |
Why?
|
| Pneumonia, Aspiration | 1 | 2007 | 22 | 0.290 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2007 | 37 | 0.290 |
Why?
|
| Hemostasis, Endoscopic | 1 | 2007 | 17 | 0.290 |
Why?
|
| End Stage Liver Disease | 2 | 2021 | 60 | 0.290 |
Why?
|
| Adult | 18 | 2023 | 21379 | 0.290 |
Why?
|
| Liver Diseases | 4 | 2014 | 193 | 0.280 |
Why?
|
| Liver | 3 | 2018 | 1118 | 0.280 |
Why?
|
| Intubation, Intratracheal | 1 | 2007 | 99 | 0.280 |
Why?
|
| Hypertension, Pulmonary | 1 | 2009 | 232 | 0.270 |
Why?
|
| Alcohol Drinking | 4 | 2014 | 805 | 0.270 |
Why?
|
| Female | 22 | 2021 | 38021 | 0.260 |
Why?
|
| Preoperative Care | 1 | 2007 | 275 | 0.250 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2007 | 185 | 0.250 |
Why?
|
| Male | 21 | 2021 | 37283 | 0.240 |
Why?
|
| Fibrosis | 3 | 2023 | 371 | 0.220 |
Why?
|
| Hypoxia | 2 | 2014 | 169 | 0.220 |
Why?
|
| Vasodilation | 2 | 2014 | 85 | 0.210 |
Why?
|
| Glucuronates | 2 | 2012 | 19 | 0.210 |
Why?
|
| Retrospective Studies | 8 | 2023 | 7268 | 0.210 |
Why?
|
| Glycerophospholipids | 2 | 2014 | 20 | 0.210 |
Why?
|
| Acetaminophen | 2 | 2021 | 111 | 0.200 |
Why?
|
| Transaminases | 1 | 2022 | 21 | 0.200 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2023 | 87 | 0.200 |
Why?
|
| Acetamides | 1 | 2021 | 17 | 0.200 |
Why?
|
| Point-of-Care Testing | 1 | 2021 | 12 | 0.200 |
Why?
|
| Blood Coagulation Disorders | 1 | 2021 | 45 | 0.200 |
Why?
|
| Hypertension, Portal | 2 | 2014 | 53 | 0.180 |
Why?
|
| Heart Failure | 1 | 2009 | 1179 | 0.180 |
Why?
|
| Hemorrhage | 1 | 2021 | 328 | 0.170 |
Why?
|
| Gastric Antral Vascular Ectasia | 1 | 2018 | 6 | 0.160 |
Why?
|
| Hyperammonemia | 1 | 2018 | 4 | 0.160 |
Why?
|
| Ornithine | 1 | 2018 | 9 | 0.160 |
Why?
|
| Neovascularization, Pathologic | 1 | 2019 | 183 | 0.150 |
Why?
|
| Intra-Aortic Balloon Pumping | 1 | 2017 | 20 | 0.150 |
Why?
|
| Machine Learning | 1 | 2019 | 170 | 0.150 |
Why?
|
| Shock, Cardiogenic | 1 | 2017 | 23 | 0.150 |
Why?
|
| alpha-Fetoproteins | 1 | 2017 | 22 | 0.150 |
Why?
|
| International Normalized Ratio | 1 | 2017 | 23 | 0.150 |
Why?
|
| Hepatic Encephalopathy | 1 | 2017 | 25 | 0.140 |
Why?
|
| Alanine Transaminase | 1 | 2017 | 137 | 0.140 |
Why?
|
| Disease Models, Animal | 2 | 2014 | 2550 | 0.140 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2019 | 331 | 0.140 |
Why?
|
| Balloon Occlusion | 1 | 2016 | 22 | 0.140 |
Why?
|
| Adolescent | 6 | 2021 | 8904 | 0.130 |
Why?
|
| Data Interpretation, Statistical | 1 | 2017 | 329 | 0.130 |
Why?
|
| Endosonography | 1 | 2016 | 177 | 0.130 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2016 | 170 | 0.120 |
Why?
|
| Treatment Outcome | 5 | 2019 | 7028 | 0.120 |
Why?
|
| Survival Analysis | 1 | 2016 | 714 | 0.120 |
Why?
|
| Portasystemic Shunt, Transjugular Intrahepatic | 1 | 2014 | 22 | 0.120 |
Why?
|
| Pulmonary Circulation | 1 | 2014 | 79 | 0.120 |
Why?
|
| ROC Curve | 3 | 2021 | 392 | 0.110 |
Why?
|
| Sulfuric Acid Esters | 1 | 2012 | 7 | 0.110 |
Why?
|
| Liver Diseases, Alcoholic | 1 | 2012 | 27 | 0.110 |
Why?
|
| Hair | 1 | 2012 | 46 | 0.100 |
Why?
|
| Planets | 1 | 2012 | 1 | 0.100 |
Why?
|
| Endovascular Procedures | 1 | 2016 | 366 | 0.100 |
Why?
|
| Young Adult | 4 | 2021 | 5710 | 0.100 |
Why?
|
| Dilatation, Pathologic | 1 | 2011 | 58 | 0.100 |
Why?
|
| Analgesics | 1 | 2012 | 118 | 0.100 |
Why?
|
| Bile Ducts | 1 | 2011 | 59 | 0.100 |
Why?
|
| Aged | 7 | 2021 | 14842 | 0.100 |
Why?
|
| Risk Factors | 4 | 2022 | 5720 | 0.100 |
Why?
|
| Cross-Sectional Studies | 3 | 2012 | 2265 | 0.100 |
Why?
|
| Child, Preschool | 2 | 2009 | 3187 | 0.100 |
Why?
|
| Chronic Pain | 1 | 2012 | 110 | 0.100 |
Why?
|
| Pain Management | 1 | 2012 | 186 | 0.090 |
Why?
|
| Quality of Life | 1 | 2019 | 1515 | 0.090 |
Why?
|
| Diagnosis, Differential | 1 | 2014 | 1140 | 0.090 |
Why?
|
| Prospective Studies | 3 | 2016 | 3703 | 0.090 |
Why?
|
| Multiple Organ Failure | 1 | 2009 | 36 | 0.080 |
Why?
|
| Immunohistochemistry | 1 | 2011 | 1174 | 0.080 |
Why?
|
| Fatal Outcome | 1 | 2009 | 164 | 0.080 |
Why?
|
| Treatment Failure | 1 | 2009 | 216 | 0.080 |
Why?
|
| Hepatectomy | 1 | 2008 | 58 | 0.080 |
Why?
|
| United States | 2 | 2017 | 7338 | 0.080 |
Why?
|
| Pilot Projects | 1 | 2011 | 1341 | 0.070 |
Why?
|
| In Situ Hybridization | 1 | 2007 | 201 | 0.070 |
Why?
|
| Sensitivity and Specificity | 3 | 2019 | 1753 | 0.070 |
Why?
|
| Cell Proliferation | 1 | 2011 | 1174 | 0.070 |
Why?
|
| Child | 2 | 2009 | 6401 | 0.070 |
Why?
|
| Primary Health Care | 2 | 2023 | 702 | 0.070 |
Why?
|
| Animals | 2 | 2014 | 20880 | 0.070 |
Why?
|
| Laparoscopy | 1 | 2008 | 237 | 0.070 |
Why?
|
| Prevalence | 2 | 2009 | 1609 | 0.070 |
Why?
|
| Biomarkers | 3 | 2019 | 1593 | 0.070 |
Why?
|
| Rats | 1 | 2014 | 5300 | 0.070 |
Why?
|
| Risk Assessment | 2 | 2022 | 2004 | 0.060 |
Why?
|
| Immunosuppressive Agents | 1 | 2007 | 514 | 0.060 |
Why?
|
| Aspartate Aminotransferases | 1 | 2023 | 87 | 0.050 |
Why?
|
| Time Factors | 2 | 2008 | 4655 | 0.050 |
Why?
|
| Thrombelastography | 1 | 2021 | 19 | 0.050 |
Why?
|
| Breath Tests | 1 | 2021 | 23 | 0.050 |
Why?
|
| Carbon Isotopes | 1 | 2021 | 54 | 0.050 |
Why?
|
| Infant | 1 | 2007 | 2891 | 0.050 |
Why?
|
| Clinical Decision-Making | 1 | 2021 | 109 | 0.050 |
Why?
|
| Follow-Up Studies | 1 | 2007 | 3256 | 0.050 |
Why?
|
| Administration, Oral | 1 | 2021 | 411 | 0.050 |
Why?
|
| Hypertension | 1 | 2009 | 1533 | 0.040 |
Why?
|
| Proof of Concept Study | 1 | 2019 | 38 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2021 | 652 | 0.040 |
Why?
|
| Placebos | 1 | 2019 | 195 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2019 | 238 | 0.040 |
Why?
|
| Platelet Count | 1 | 2018 | 100 | 0.040 |
Why?
|
| Ammonia | 1 | 2018 | 28 | 0.040 |
Why?
|
| Glutamine | 1 | 2018 | 45 | 0.040 |
Why?
|
| Gastroscopy | 1 | 2018 | 45 | 0.040 |
Why?
|
| Kidney Function Tests | 1 | 2018 | 114 | 0.040 |
Why?
|
| Gastric Mucosa | 1 | 2018 | 77 | 0.040 |
Why?
|
| Disease Progression | 1 | 2021 | 1037 | 0.040 |
Why?
|
| Phenols | 1 | 2018 | 73 | 0.040 |
Why?
|
| Acetates | 1 | 2018 | 74 | 0.040 |
Why?
|
| Linear Models | 1 | 2019 | 521 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2019 | 307 | 0.040 |
Why?
|
| Echocardiography | 1 | 2019 | 515 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2019 | 621 | 0.030 |
Why?
|
| Cause of Death | 1 | 2016 | 241 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2019 | 1738 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 1465 | 0.030 |
Why?
|
| Hemodynamics | 1 | 2017 | 705 | 0.030 |
Why?
|
| Patient Selection | 1 | 2018 | 592 | 0.030 |
Why?
|
| Critical Care | 1 | 2016 | 263 | 0.030 |
Why?
|
| Survival Rate | 1 | 2016 | 1055 | 0.030 |
Why?
|
| Substance Abuse Detection | 1 | 2012 | 66 | 0.030 |
Why?
|
| Extraterrestrial Environment | 1 | 2012 | 1 | 0.030 |
Why?
|
| Stars, Celestial | 1 | 2012 | 1 | 0.030 |
Why?
|
| Spacecraft | 1 | 2012 | 2 | 0.030 |
Why?
|
| Pain Measurement | 1 | 2012 | 328 | 0.020 |
Why?
|
| Space Flight | 1 | 2012 | 40 | 0.020 |
Why?
|
| Activities of Daily Living | 1 | 2012 | 319 | 0.020 |
Why?
|
| Antimetabolites | 1 | 2010 | 17 | 0.020 |
Why?
|
| Sex Factors | 1 | 2014 | 1265 | 0.020 |
Why?
|
| Antitubercular Agents | 1 | 2010 | 57 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2012 | 1040 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2014 | 1549 | 0.020 |
Why?
|
| Antifungal Agents | 1 | 2010 | 108 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2014 | 1329 | 0.020 |
Why?
|
| Age Factors | 1 | 2014 | 1860 | 0.020 |
Why?
|
| Anticonvulsants | 1 | 2010 | 223 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 2077 | 0.020 |
Why?
|
| Hemangioma | 1 | 2008 | 51 | 0.020 |
Why?
|
| Blood Loss, Surgical | 1 | 2008 | 79 | 0.020 |
Why?
|
| Cysts | 1 | 2008 | 70 | 0.020 |
Why?
|
| Pain, Postoperative | 1 | 2008 | 214 | 0.020 |
Why?
|
| Length of Stay | 1 | 2008 | 780 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2010 | 1026 | 0.010 |
Why?
|
| South Carolina | 1 | 2008 | 2752 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2008 | 1615 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2008 | 4843 | 0.010 |
Why?
|